Progenics rises on C diff deal with MedImmune
This article was originally published in Scrip
Executive Summary
Progenics Pharmaceuticals' inked a deal for its preclinical Clostridium difficile antibodies with AstraZeneca unit MedImmune, which is paying an undisclosed amount for the rights to program.